Skip to main content

Table 3 Multivariate analysis for pCR according to treatment groups

From: Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

Platinum-containing chemotherapy (groups A1 + A2)    
  HR 95% CI P value HR 95% CI P value
Age 0.89 0.809–0.980 0.0066 0.88 0.797–0.973 0.0038
Dose 1.041 0.970–1.117 0.25 1.029 0.963–1.099 0.38
Treatment    0.32    0.19
A1 Reference Reference
A2 0.39 0.29
Intratumoral CD4 1.009 0.996–1.022 0.018    
Stromal CD4     1.002 1.000–1.004 0.022
Non-platinum-containing chemotherapy (groups B1 + B2)    
  HR 95% CI P value HR 95% CI P value
Age 1.02 0.893–1.169 0.75 1.009 0.883–1.153 0.89
Dose 1.091 0.975–1.222 0.022 1.096 0.968–1.241 0.029
Treatment    0.42    0.70
B1 Reference Reference
B2 2.47 1.573
Intratumoral CD4 0.998 0.994–1.003 0.38    
Stromal CD4     1.0003 0.998–1.002 0.73
  1. A1 group taking paclitaxel + carboplatin, A2 group taking eribulin + carboplatin, B1 eribulin + cyclophosphamide, B2 eribulin + capecitabine, CI confidence interval, HR hazard ratio, Dose dose of paclitaxel in group A1, eribulin in groups A2, B1 and B2
  2. Statistically significant P values are shown in italics